{"organizations": [], "uuid": "194843ef2e80c6081b3c91e12c1d9dd686ddd7b8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530660?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Advaxis gets $20mm through private share sale to Sectoral Asset Management", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Advaxis gets $20mm through private share sale to Sectoral Asset Management", "spam_score": 0.0, "site_type": "news", "published": "2015-08-29T02:40:00.000+03:00", "replies_count": 0, "uuid": "194843ef2e80c6081b3c91e12c1d9dd686ddd7b8"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530660?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Advaxis gets $20mm through private share sale to Sectoral Asset Management", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Advaxis gets $20mm through private share sale to Sectoral Asset Management Deal Date: Aug-01-2015 / Deal # 201530660 Executive Summary \nCancer immunotherapies firm Advaxis Inc. grossed $20mm by selling 1.4mm shares at $13.91 (a 5% discount) to Sectoral Asset Management. Concurrent with the private placement, Advaxis also received $5mm through sale of shares to Knight Therapeutics in connection with a new alliance between the two companies in which Knight gets Canadian commercialization rights to all of Advaxis' candidates.", "external_links": [], "published": "2015-08-29T02:40:00.000+03:00", "crawled": "2015-08-29T18:11:10.606+03:00", "highlightTitle": ""}